Molecular characterisation of KRAS mutations in non-small cell lung cancer across all stages
This study underscores the importance of assessing KRAS status and subtypes in NSCLC, particularly in early-stage disease, due to their association with metastatic risk. This could have relevance in treatment strategies and subsequent monitoring, which could necessarily be closer in higher risk patients. Moreover, while PD-L1 status shows potential as a prognostic factor in KRASm patients, further research is needed to confirm this relationship.
Authors
- Alicia Carrasco
- Sandra Soriano
- Carla Climent (ORCID: https://orcid.org/0000-0002-5832-3502)
- Miguel Ángel Seguí (ORCID: https://orcid.org/0000-0002-5103-6746)
- Natalia Vila López (ORCID: https://orcid.org/0000-0001-9438-3337)
- Julia Giner
- Marta Blázquez Estrada (ORCID: https://orcid.org/0000-0003-3348-9992)
- Mireia Busquets
- O. Cano Cano
- P. Andreu Cobo (ORCID: https://orcid.org/0009-0003-1613-9306)
- Marina Sierra
- Laia Vilà (ORCID: https://orcid.org/0000-0002-1211-5804)
- Monica Fragio
- R. Jañez Carrera
Institutions
- Corporació Sanitària Parc Taulí (ES)
- Hospital de Sabadell (ES)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-05-27
- DOI
- https://doi.org/10.3332/ecancer.2025.1914
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00